chr12-68809243-A-G
Position:
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM2BP4_Moderate
The NM_002392.6(MDM2):āc.50A>Gā(p.Asp17Gly) variant causes a missense change. The variant allele was found at a frequency of 0.0000205 in 1,461,870 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ).
Frequency
Genomes: not found (cov: 33)
Exomes š: 0.000021 ( 0 hom. )
Consequence
MDM2
NM_002392.6 missense
NM_002392.6 missense
Scores
5
14
Clinical Significance
Conservation
PhyloP100: 5.41
Genes affected
MDM2 (HGNC:6973): (MDM2 proto-oncogene) This gene encodes a nuclear-localized E3 ubiquitin ligase. The encoded protein can promote tumor formation by targeting tumor suppressor proteins, such as p53, for proteasomal degradation. This gene is itself transcriptionally-regulated by p53. Overexpression or amplification of this locus is detected in a variety of different cancers. There is a pseudogene for this gene on chromosome 2. Alternative splicing results in a multitude of transcript variants, many of which may be expressed only in tumor cells. [provided by RefSeq, Jun 2013]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 0 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (MetaRNN=0.21857804).
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD3 genomes
Cov.:
33
GnomAD4 exome AF: 0.0000205 AC: 30AN: 1461870Hom.: 0 Cov.: 31 AF XY: 0.0000151 AC XY: 11AN XY: 727238
GnomAD4 exome
AF:
AC:
30
AN:
1461870
Hom.:
Cov.:
31
AF XY:
AC XY:
11
AN XY:
727238
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome Cov.: 33
GnomAD4 genome
Cov.:
33
TwinsUK
AF:
AC:
1
ALSPAC
AF:
AC:
0
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
Accelerated tumor formation, susceptibility to Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 01, 2023 | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C15"). This variant has not been reported in the literature in individuals affected with MDM2-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces aspartic acid, which is acidic and polar, with glycine, which is neutral and non-polar, at codon 17 of the MDM2 protein (p.Asp17Gly). - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Benign
.;T;T;T;D;T;.;.;.;.;T;.;.;.;.;.;T;T;.
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Benign
N
LIST_S2
Uncertain
D;D;D;D;D;D;D;D;.;.;.;D;D;D;.;D;D;.;.
M_CAP
Benign
D
MetaRNN
Benign
T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T
MetaSVM
Benign
T
MutationAssessor
Benign
.;.;.;.;L;.;.;.;.;.;.;L;L;.;.;L;.;.;.
PrimateAI
Uncertain
T
PROVEAN
Benign
.;N;D;N;D;D;D;D;D;D;D;D;N;N;D;D;N;N;D
REVEL
Benign
Sift
Uncertain
.;D;D;D;T;T;T;T;.;D;D;T;D;T;D;D;T;D;.
Sift4G
Uncertain
D;D;D;D;D;D;D;T;D;D;D;T;D;D;D;D;D;T;D
Polyphen
B;.;P;B;B;.;.;.;.;.;P;B;P;P;.;P;.;.;.
Vest4
MutPred
0.21
.;Gain of catalytic residue at V8 (P = 0.0045);Gain of catalytic residue at V8 (P = 0.0045);.;Gain of catalytic residue at V8 (P = 0.0045);Gain of catalytic residue at V8 (P = 0.0045);Gain of catalytic residue at V8 (P = 0.0045);Gain of catalytic residue at V8 (P = 0.0045);Gain of catalytic residue at V8 (P = 0.0045);Gain of catalytic residue at V8 (P = 0.0045);Gain of catalytic residue at V8 (P = 0.0045);Gain of catalytic residue at V8 (P = 0.0045);Gain of catalytic residue at V8 (P = 0.0045);Gain of catalytic residue at V8 (P = 0.0045);Gain of catalytic residue at V8 (P = 0.0045);Gain of catalytic residue at V8 (P = 0.0045);Gain of catalytic residue at V8 (P = 0.0045);.;.;
MVP
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at